Pharmacokinetic properties of inhaled corticosteroids
| Oral bioavailability% | Protein-binding% | ClearanceL·h-1 | VdL | Half-lifeh | |
| BDP | 15 | 87 | 230 | 20 | 0.1 |
| BMP | 26 | NA | 120# | 424# | 2.7 |
| BUD | 11 | 88 | 84 | 183 | 2.8 |
| CIC | <1 | 99 | 152 | 207 | 0.4 |
| des-CIC | <1 | 99 | 396# | 1190# | 3.6−5.1 |
| FLU | 7 | 80 | 58 | 96 | 1.6 |
| FP | <1 | 90 | 69 | 318 | 14.4 |
| MF | <1< | 98 | 53.5 | 332 | 4.5 |
| TAA | 23 | 71 | 37 | 103 | 2.0 |
Vd: volume of distribution; BDP: beclometasone dipropionate; BMP: beclometasone monopropionate; BUD: budesonide; CIC: ciclesonide; des-CIC: desisobutyryl-CIC; FLU: flunisolide; FP: fluticasone propionate; MF: mometasone furoate; TAA: triamcinolone acetonide; NA: not available. #: apparent maximum approximation based on complete conversion of the parent compound. Data taken and collated from 21, 35, 46–53.